Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025

As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology

Read more at prnewswire.com